The MFN drug pricing policy ties U.S. list prices to those in select high-income countries, creating immediate international benchmarking for launch prices and sustained downward pressure on pricing.

Pharma companies with global portfolios, BD teams negotiating licensing and M&A deals, investors assessing asset valuations, and patients in the U.S. and reference countries.

What should teams watch next?

Monitor regulatory updates on MFN implementation, shifts in payer mix and global price gaps, and changes in deal terms (e.g., milestone structures, royalty rates) as companies adapt.

MFN Drug Pricing Impact on Pharma Licensing Deals

MFN Drug Pricing Reshapes International Life Sciences Licensing Deals

0% citation coverage

The Most Favored Nation (MFN) drug pricing policy is fundamentally altering the landscape for international life sciences licensing deals. This analysis explores how MFN pricing introduces sustained downward pressure on U.S. list prices, reshapes valuation and diligence, and creates new strategic considerations for BD teams and investors.

Dr. Elena Rossi PhD Pharmaceutical Sciences · EMA Regulatory Affairs Editor

Reviewed by Dr. Sarah Chen Pharmaceutical Sciences Editor

Friday, June 5, 2026 4 min read Updated Jun 5, 2026 Your watchlist

Executive Summary

MFN pricing ties U.S. drug prices to those in select high-income countries, creating immediate downward pressure on list prices and forcing launch-price decisions in ex-U.S. markets to carry direct U.S. consequences.

BD teams and investors must adjust asset valuation, milestone structures, and royalty assumptions to account for the policy’s introduction of greater pricing uncertainty into licensing and M&A deals.

Industry opinion remains sharply divided: 38% of experts surveyed by Cornell’s Health Policy Center agree MFN will substantially reduce pharmaceutical innovation, while 28% disagree and 32% are uncertain.

Regulatory	high
Commercial	high
Competitive	medium
Investment	high

Regulatory

high

Commercial

high

Competitive

medium

Investment

high

MFN Drug Pricing Reshapes International Life Sciences Licensing Deals

The Most Favored Nation (MFN) drug pricing policy is fundamentally altering the landscape for international life sciences licensing deals, introducing sustained downward pressure on U.S. list prices while reshaping valuation, diligence, and strategic considerations for BD teams and investors.

Key Takeaways

MFN pricing ties U.S. drug prices to those in select high-income countries, creating immediate downward pressure on list prices and forcing launch-price decisions in ex-U.S. markets to carry direct U.S. consequences.
BD teams and investors must adjust asset valuation, milestone structures, and royalty assumptions to account for the policy’s introduction of greater pricing uncertainty into licensing and M&A deals.
Industry opinion remains sharply divided: 38% of experts surveyed by Cornell’s Health Policy Center agree MFN will substantially reduce pharmaceutical innovation, while 28% disagree and 32% are uncertain.

The Development

The MFN drug pricing mechanism, detailed by Skadden, Arps, Slate, Meagher & Flom LLP, directly ties U.S. list prices for new drugs to those in a basket of high-income reference countries. Because launch prices are now subject to immediate international benchmarking, a pricing decision in Germany or Japan can instantly set the U.S. ceiling. This reverses the traditional sequence: instead of setting a high U.S. price first and then negotiating discounts abroad, companies must now factor in the global average from the outset.

This structural shift has triggered fresh debate about the policy’s net effect on innovation. The Cornell survey of health policy panelists found that 38% agreed or strongly agreed that MFN would substantially reduce pharmaceutical innovation benefiting U.S. patients, while 28% disagreed or strongly disagreed. The remaining 32% were uncertain, reflecting the still-unfolding nature of the rule’s implementation. Critics argue that the policy does little to address structural drivers of high U.S. drug costs, including patent system abuse, as outlined by the Petrie-Flom Center at Harvard Law School. The White House, meanwhile, has projected substantial federal savings from the framework, detailed in its May 2026 research report.

Implications for Pharma Teams

For BD teams and investors, MFN pricing fundamentally alters the calculus for international licensing deals by introducing greater pricing uncertainty that directly affects asset valuation, deal terms, and strategic planning. During diligence, companies must weigh payer mix and global price gaps, since a drug’s price in a reference country can ripple back to constrain U.S. revenue potential. Royalty rates, milestone triggers, and market-access assumptions all need reassessment to reflect the downward pressure MFN imposes on launch prices.

The shift also reshapes M&A strategy. Some companies are already structuring deals that tie payments to actual post-launch pricing outcomes rather than fixed milestones. Others are re-evaluating their market entry strategies, since an early low price in a reference country could lock in a lower U.S. list price for years. Skadden’s analysis notes that the policy’s impact extends beyond the largest pharma players—smaller biotechs relying on out-licensing to U.S. partners may find their assets valued differently because their partners’ U.S. pricing flexibility is constrained.

While industry performance has been lackluster, with the DRG biotech index down roughly 10% over the past year, the MFN policy is not likely to dampen overall deal appetite. Instead, the pressure is shifting how deals are structured and how risk is allocated, making pricing-diligence capabilities a core competitive advantage for BD teams.

Frequently Asked Questions

Is MFN good or bad?

Opinion is split. In a Cornell Health Policy Center survey, 38% of panelists agreed MFN would substantially reduce pharmaceutical innovation benefiting U.S. patients, 28% disagreed, and 32% were uncertain. The policy’s ultimate outcome depends on implementation details and how companies adapt their global pricing strategies.

How does MFN affect pricing?

MFN introduces sustained downward pressure on U.S. list prices by tying them directly to prices in select high-income reference countries. Because launch prices are now subject to immediate international benchmarking, decisions made in ex-U.S. markets can carry direct consequences for U.S. pricing and access outcomes, as detailed by Skadden.

What is MFN pricing?

The Most Favored Nation drug pricing policy links the U.S. price of a new drug to the lowest price available in a set of comparable high-income countries. It effectively applies international reference pricing to the U.S. market for the first time, requiring companies to consider global price benchmarks at launch rather than setting prices independently.